Prolonged Partial Thromboplastin Time (PTT) Management

Causes of Prolonged PTT

The European Society of Cardiology recommends that therapy with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is a common cause of prolonged PTT 1, 2
The American College of Chest Physicians suggests that heparin-induced thrombocytopenia (HIT) is a cause of prolonged PTT, and recommends monitoring platelet count every 2 days during treatment 1, 3

The American College of Cardiology recommends an initial evaluation to verify if the patient is receiving anticoagulants, and to review history of bleeding or thrombosis 1, 2, 4
The European Society of Intensive Care Medicine suggests that laboratory tests, including a 50:50 mixing study with normal plasma, should be performed to diagnose the cause of prolonged PTT 5

The American Heart Association recommends that patients receiving UFH should be monitored with PTT, with a target range of 1.5-2.5 times the control value 6, 1, 7
The European Society of Cardiology suggests that when the basal PTT is prolonged, monitoring with anti-Xa levels (target range: 0.3-0.6 UI/mL) should be performed, and not to use PTT exclusively to adjust the dose 6, 1
The American College of Chest Physicians recommends that patients with HIT should have their heparin suspended if there is a sudden decrease in platelets (<100,000/μL or >30%), and to consider alternative anticoagulants such as argatroban, danaparoid sodium, or recombinant hirudin 1, 3, 8

The European Society of Cardiology recommends that for UFH, protamine sulfate should be administered IV, with a dose of 1 mg per 100 units of heparin administered in the last 2-3 hours (maximum dose: 50 mg) 5, 7
The American College of Cardiology suggests that for LMWH, protamine sulfate should be administered IV slowly over 10 minutes, with a dose of 1 mg of protamine per 1 mg of enoxaparina administered in the last 8 hours 5

The American College of Chest Physicians recommends that in patients with clinical coagulopathy and evident bleeding, platelets should be maintained >50,000/μL, fibrinogen >150 mg/dL, and PT and PTT should be normalized 4
The European Society of Intensive Care Medicine suggests that routine correction with fresh frozen plasma is not recommended in patients with prolonged PTT without active bleeding 4

A comprehensive laboratory evaluation for patients with prolonged PTT should include a complete blood count with platelet assessment, prothrombin time (PT) and fibrinogen levels, and blood smear morphology to evaluate for schistocytes or other abnormalities, as recommended by the American Society of Clinical Oncology 9
Consider ADAMTS13 activity level and inhibitor titer if thrombotic thrombocytopenic purpura is suspected in patients with prolonged PTT, according to the American Society of Clinical Oncology 9

For patients on unfractionated heparin (UFH) therapy with prolonged PTT, the American College of Chest Physicians recommends monitoring with anti-Xa levels (target range: 0.3-0.7 IU/mL) instead of PTT, with a strength of evidence rated as high 10
For mild factor deficiencies (5%-40% of normal factor activity), the American Society of Hematology suggests considering factor replacement therapy based on the specific deficiency, with a moderate strength of evidence 11
For moderate to severe deficiencies (<5% of normal factor activity), the American Society of Hematology recommends consulting hematology and administering factor replacement based on the Bethesda unit level of inhibitor, with a high strength of evidence 11, 12

The American College of Clinical Pharmacy notes that multiple medications can affect PTT, including heparin, direct thrombin inhibitors, and certain antibiotics, which should be considered when managing patients with prolonged PTT 9

Liver disease affecting coagulation factor synthesis can lead to prolonged PTT, as noted by the World Journal of Emergency Surgery 13
Disseminated intravascular coagulation (DIC) in cancer or sepsis can cause prolonged PTT, according to the Journal of Thrombosis and Haemostasis 14

For patients on unfractionated heparin (UFH) with renal impairment (CrCl <30 mL/min), the European Heart Journal recommends UFH with careful monitoring instead of low molecular weight heparin (LMWH) 15
For patients requiring surgery or invasive procedures with active bleeding, the World Journal of Emergency Surgery suggests maintaining PT/aPTT within normal range 16

In trauma patients, a PTT >37.4 seconds may be a contraindication for thrombolytic therapy, as indicated by the journal Stroke 17
In patients with cancer, decreasing platelet count along with prolonged PTT may indicate DIC, even if other parameters appear normal, according to the Journal of Thrombosis and Haemostasis 14
In patients with chronic kidney disease requiring anticoagulation, the European Heart Journal recommends UFH infusion adjusted to aPTT when CrCl is <30 mL/min 15

Failing to consider timing of blood sampling relative to anticoagulant administration when interpreting PTT results is a common pitfall, as noted by the European Heart Journal 18